About this Journal Submit a Manuscript Table of Contents
Advances in Virology
Volume 2012 (2012), Article ID 815465, 10 pages
http://dx.doi.org/10.1155/2012/815465
Research Article

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus

1Department of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA
2Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
3Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA

Received 1 March 2012; Revised 27 June 2012; Accepted 7 July 2012

Academic Editor: Julia G. Prado

Copyright © 2012 Bonnie Reinhart et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Grandi, P. Peruzzi, B. Reinhart, J. B. Cohen, E. A. Chiocca, and J. C. Glorioso, “Design and application of oncolytic HSV vectors for glioblastoma therapy,” Expert Review of Neurotherapeutics, vol. 9, no. 4, pp. 505–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Hu, M. J. Booth, G. Tripuraneni et al., “A novel HSV-1 virus, JS1/34.5-/47—purges contaminating breast cancer cells from bone marrow,” Clinical Cancer Research, vol. 12, no. 22, pp. 6853–6862, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Markert, M. D. Medlock, S. D. Rabkin et al., “Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a phase I trial,” Gene Therapy, vol. 7, no. 10, pp. 867–874, 2000. View at Scopus
  4. V. Papanastassiou, R. Rampling, M. Fraser et al., “The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into malignant glioma: a proof of principle study,” Gene Therapy, vol. 9, no. 6, pp. 398–406, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Rampling, G. Cruickshank, V. Papanastassiou et al., “Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma,” Gene Therapy, vol. 7, no. 10, pp. 859–866, 2000. View at Scopus
  6. N. N. Senzer, H. L. Kaufman, T. Amatruda et al., “Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5763–5771, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. D. Everett and A. Orr, “Herpes simplex virus type 1 regulatory protein ICP0 aids infection in cells with a preinduced interferon response but does not impede interferon-induced gene induction,” Journal of Virology, vol. 83, no. 10, pp. 4978–4983, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. W. P. Halford, C. Weisend, J. Grace et al., “ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency,” Virology Journal, vol. 3, article 44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. A. Leib, T. E. Harrison, K. M. Laslo, M. A. Machalek, N. J. Moorman, and H. W. Virgin, “Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo,” Journal of Experimental Medicine, vol. 189, no. 4, pp. 663–672, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Gu and B. Roizman, “Herpes simplex virus-infected cell protein 0 blocks the silencing of viral DNA by dissociating histone deacetylases from the CoREST-REST complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 43, pp. 17134–17139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Cai and P. A. Schaffer, “Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells,” Journal of Virology, vol. 66, no. 5, pp. 2904–2915, 1992. View at Scopus
  12. J. Chen and S. Silverstein, “Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression,” Journal of Virology, vol. 66, no. 5, pp. 2916–2927, 1992. View at Scopus
  13. C. Boutell, R. Everett, J. Hilliard, P. Schaffer, A. Orr, and D. Davido, “Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner,” Journal of Virology, vol. 82, no. 21, pp. 10647–10656, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Boutell, A. Orr, and R. D. Everett, “PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0,” Journal of Virology, vol. 77, no. 16, pp. 8686–8694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Boutell, S. Sadis, and R. D. Everett, “Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro,” Journal of Virology, vol. 76, no. 2, pp. 841–850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Chelbi-Alix and H. De Thé, “Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins,” Oncogene, vol. 18, no. 4, pp. 935–941, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. R. D. Everett, “Herpes simplex virus type 1 regulatory protein ICP0 does not protect cyclins D1 and D3 from degradation during infection,” Journal of Virology, vol. 78, no. 18, pp. 9599–9604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Lin, R. S. Noyce, S. E. Collins, R. D. Everett, and K. L. Mossman, “The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes,” Journal of Virology, vol. 78, no. 4, pp. 1675–1684, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Lomonte, K. F. Sullivan, and R. D. Everett, “Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0,” Journal of Biological Chemistry, vol. 276, no. 8, pp. 5829–5835, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. N. D. Stow and E. C. Stow, “Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110,” Journal of General Virology, vol. 67, no. 12, pp. 2571–2585, 1986. View at Scopus
  21. W. R. Sacks and P. A. Schaffer, “Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture,” Journal of Virology, vol. 61, no. 3, pp. 829–839, 1987. View at Scopus
  22. F. Yao and P. A. Schaffer, “An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1,” Journal of Virology, vol. 69, no. 10, pp. 6249–6258, 1995. View at Scopus
  23. P. T. Sobol, J. L. Hummel, R. M. Rodrigues, and K. L. Mossman, “PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses,” Gene Therapy, vol. 16, no. 9, pp. 1077–1087, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Hummel, E. Safroneeva, and K. L. Mossman, “The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma,” Molecular Therapy, vol. 12, no. 6, pp. 1101–1110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Fulci, L. Breymann, D. Gianni et al., “Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 34, pp. 12873–12878, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Friedman, J. P. Tian, G. Fulci, E. A. Chiocca, and J. Wang, “Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity,” Cancer Research, vol. 66, no. 4, pp. 2314–2319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Adams, K. Besken, C. Oberdörfer, C. R. MacKenzie, D. Rüßing, and W. Däubener, “Inhibition of human herpes simplex virus type 2 by interferon γ and tumor necrosis factor α is mediated by indoleamine 2,3-dioxygenase,” Microbes and Infection, vol. 6, no. 9, pp. 806–812, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. D. H. Munn and A. L. Mellor, “Indoleamine 2,3-dioxygenase and tumor-induced tolerance,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1147–1154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Zamanakou, A. E. Germenis, and V. Karanikas, “Tumor immune escape mediated by indoleamine 2,3-dioxygenase,” Immunology Letters, vol. 111, no. 2, pp. 69–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. B. Katz, A. J. Muller, and G. C. Prendergast, “Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape,” Immunological Reviews, vol. 222, no. 1, pp. 206–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. C. S. Hong, W. Fellows, A. Niranjan et al., “Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection,” Gene Therapy, vol. 17, no. 10, pp. 1200–1205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Tyminski, S. LeRoy, K. Terada et al., “Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan,” Cancer Research, vol. 65, no. 15, pp. 6850–6857, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Markert, P. G. Liechty, W. Wang et al., “Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM,” Molecular Therapy, vol. 17, no. 1, pp. 199–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Markert, J. N. Parker, D. J. Buchsbaum, W. E. Grizzle, G. Y. Gillespie, and R. J. Whitley, “Oncolytic HSV-1 for the treatment of brain tumours,” Herpes, vol. 13, no. 3, pp. 66–71, 2006. View at Scopus
  35. T. Mineta, S. D. Rabkin, T. Yazaki, W. D. Hunter, and R. L. Martuza, “Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas,” Nature Medicine, vol. 1, no. 9, pp. 938–943, 1995. View at Scopus
  36. K. L. Mossman and J. R. Smiley, “Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication,” Journal of Virology, vol. 76, no. 4, pp. 1995–1998, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. W. R. Sacks and P. A. Schaffer, “Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture,” Journal of Virology, vol. 61, no. 3, pp. 829–839, 1987. View at Scopus
  38. F. J. Jenkins and B. Roizman, “Herpes simplex virus 1 recombinants with noninverting genomes frozen in different isomeric arrangements are capable of independent replication,” Journal of Virology, vol. 59, no. 2, pp. 494–499, 1986. View at Scopus
  39. R. J. Prestwich, F. Errington, R. M. Diaz et al., “The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon,” Human gene therapy, vol. 20, no. 10, pp. 1119–1132, 2009. View at Scopus
  40. T. Miyazaki, K. Moritake, K. Yamada et al., “Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy: laboratory investigation,” Journal of Neurosurgery, vol. 111, no. 2, pp. 230–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. G. J. Guillemin, K. M. Cullen, C. K. Lim et al., “Characterization of the kynurenine pathway in human neurons,” Journal of Neuroscience, vol. 27, no. 47, pp. 12884–12892, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Okano, W. J. Storkus, W. H. Chambers, I. F. Pollack, and H. Okada, “Identification of a novel HLA-A 0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain,” Clinical Cancer Research, vol. 8, pp. 2851–2855, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. M. R. Alvira, W. F. Goins, J. B. Cohen, and J. C. Glorioso, “Genetic studies exposing the splicing events involved in herpes simplex virus type 1 latency-associated transcript production during lytic and latent infection,” Journal of Virology, vol. 73, no. 5, pp. 3866–3876, 1999. View at Scopus
  44. M. Tsvitov, A. R. Frampton, W. A. Shah et al., “Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection,” Virology, vol. 360, no. 2, pp. 477–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus